Short answer
Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Nkarta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release scheduled for August 10, 2026
- Detailed financial figures available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- NKX019 enrollment continues across six autoimmune indications at 4 billion cells per dose, with 12 billion cells per three-dose cycle
- Outpatient dosing now underway at community sites, potentially improving trial access and supporting scalable treatment delivery
- Initial Ntrust-1 and Ntrust-2 clinical data expected at a 2026 medical conference, creating the next major valuation catalyst
- Cash, restricted cash and investments totaled $243.2 million at June 30, 2026, with management projecting funding into 2029
- Q2 net loss widened to $40.4 million from $23.0 million, while R&D increased to $29.0 million and G&A to $14.1 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nkarta, Inc. 8-K filings
Get the next NKTX 8-K as it lands
Follow NKTX for push alerts, or ask the research agent what this filing means.